TY - JOUR
T1 - Cardiac involvement in scleroderma
AU - Deswal, A.
AU - Follansbee, W. P.
PY - 1996
Y1 - 1996
N2 - In summary, cardiac involvement in systemic sclerosis can be manifested as myocardial disease, pericardial disease, conduction system disease, or arrhythmias. Clinical cardiac involvement is a poor prognostic factor. Asymptomatic cardiac abnormalities are frequent, and all cardiac abnormalities are seen more often in diffuse scleroderma. Unlike other organs, the role of vascular involvement is unclear. At present, treatment of cardiac scleroderma is essentially symptomatic and empiric. The role of vasodilation and immunosuppression needs further exploration.
AB - In summary, cardiac involvement in systemic sclerosis can be manifested as myocardial disease, pericardial disease, conduction system disease, or arrhythmias. Clinical cardiac involvement is a poor prognostic factor. Asymptomatic cardiac abnormalities are frequent, and all cardiac abnormalities are seen more often in diffuse scleroderma. Unlike other organs, the role of vascular involvement is unclear. At present, treatment of cardiac scleroderma is essentially symptomatic and empiric. The role of vasodilation and immunosuppression needs further exploration.
UR - http://www.scopus.com/inward/record.url?scp=0029905888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029905888&partnerID=8YFLogxK
U2 - 10.1016/S0889-857X(05)70304-5
DO - 10.1016/S0889-857X(05)70304-5
M3 - Article
C2 - 8923599
AN - SCOPUS:0029905888
SN - 0889-857X
VL - 22
SP - 841
EP - 860
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
IS - 4
ER -